STOCK TITAN

GRI Bio (GRI) S-3 Filings

GRI NASDAQ

Here are the S-3 shelf registrations from GRI Bio, Inc. (GRI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow GRI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRI filings page.

Rhea-AI Summary

GRI Bio, Inc. has filed a shelf registration on Form S-3 to offer up to $250,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time. Specific terms and pricing will be set in future prospectus supplements.

The company’s common stock trades on The Nasdaq Capital Market under the symbol GRI, with a last reported price of $5.55 per share on January 26, 2026. On January 23, 2026, GRI Bio effected a one-for-28 reverse stock split, and share and warrant figures in the prospectus reflect this adjustment. As of January 26, 2026, 525,358 shares of common stock were outstanding.

GRI Bio is a clinical-stage biopharmaceutical company developing therapies for inflammatory, fibrotic and autoimmune diseases. Its lead candidate, GRI-0621, targets idiopathic pulmonary fibrosis, and the pipeline also includes GRI-0803 for autoimmune disorders such as lupus and multiple sclerosis. Net proceeds from future sales under the shelf are expected to be used for general corporate purposes, including working capital and other general and administrative needs.